Alan S. Go, MD; Elaine M. Hylek, MD, MPH; Leila H. Borowsky, MPH; Kathleen A. Phillips, BA; Joe V. Selby, MD, MPH; Daniel E. Singer, MD
Acknowledgments: The authors thank Vernal Mason and Lori E. Henault for helping to coordinate this project and for technical support.
Grant Support: By Public Health Services research grant AG15478 from the National Institute on Aging.
Requests for Reprints: Alan S. Go, MD, Division of Research, Kaiser Permanente Medical Care Program (Northern California), 3505 Broadway Street, 12th Floor, Oakland, CA 94611-5714; e-mail, email@example.com. For reprint orders in quantities exceeding 100, please contact the Reprints Coordinator; phone, 215-351-2657; e-mail, firstname.lastname@example.org.
Current Author Addresses: Dr. Go and Ms. Phillips: Division of Research, Kaiser Permanente Medical Care Program (Northern California), 3505 Broadway Street, 12th Floor, Oakland, CA 94611-5714.
Drs. Hylek and Singer and Ms. Borowsky: Medical Practices Evaluation Unit, 50 Staniford Street, 9th Floor, Boston, MA 02114.
Dr. Selby: Division of Research, 3505 Broadway Street, 13th Floor, Oakland, CA 94611.
Go A., Hylek E., Borowsky L., Phillips K., Selby J., Singer D.; Warfarin Use among Ambulatory Patients with Nonvalvular Atrial Fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. Ann Intern Med. 1999;131:927-934. doi: 10.7326/0003-4819-131-12-199912210-00004
Download citation file:
Published: Ann Intern Med. 1999;131(12):927-934.
Atrial fibrillation is the most common, potent risk factor for ischemic stroke. Nonrheumatic atrial fibrillation, the predominant form in the United States, occurs in nearly 6% of persons 65 years of age or older (1). Atrial fibrillation is an independent risk factor for stroke, increasing the annual risk by fivefold and accounting for approximately 15% of all strokes in the United States (2). Over the past decade, multiple randomized trials have demonstrated that warfarin therapy can reduce the average annual risk for ischemic stroke by two thirds, from 4.5% to 1.4%, in patients with nonvalvular atrial fibrillation (2). This benefit was accompanied by a relatively low annual bleeding rate (1.3%) (2-4). However, recent data suggest that these dramatic findings have not been adequately implemented in clinical practice (5-9).
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Cardiology, Neurology, Rhythm Disorders and Devices, Stroke, Prevention/Screening.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only